Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

menarini international operation - dexketoprofentrometamol - injektions-/infusionsvæske, opløsning - 50 mg/2ml (25 mg/ml)

Den Europæiske Union - dansk - EMA (European Medicines Agency)

bluebird bio (netherlands) b.v. - elivaldogene autotemcel - adrenoleukodystrophy - andre narkotika stoffer - treatment of early cerebral adrenoleukodystrophy in patients less than 18 years of age, with an abcd1 genetic mutation, and for whom a human leukocyte antigen (hla) matched sibling haematopoietic stem cell donor is not available.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

abbvie a/s - carbidopa, levodopa - enteralgel - 20+5 mg/ml

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

campuspharma ab - epoprostenolnatrium - pulver og solvens til infusionsvæske, opløsning - 1,5 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

campuspharma ab - epoprostenolnatrium - pulver og solvens til infusionsvæske, opløsning - 500 mikrogram

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

pfizer aps - methylprednisolonnatriumsuccinat - pulver og solvens til injektionsvæske, opløsning - 1 g

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

pfizer aps - methylprednisolonnatriumsuccinat - pulver og solvens til injektionsvæske, opløsning - 500 mg

Den Europæiske Union - dansk - EMA (European Medicines Agency)

a. menarini industrie farmaceutiche riunite s.r.l. - delafloxacin meglumine - ef-erhvervede infektioner - antibakterielle midler til systemisk brug, - quofenix is indicated for the treatment of the following infections in adults:acute bacterial skin and skin structure infections (absssi),community-acquired pneumonia (cap), when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment of these infections (see sections 4. 4 og 5. det bør overvejes at officielle vejledning om hensigtsmæssig brug af antibakterielle midler..

Den Europæiske Union - dansk - EMA (European Medicines Agency)

kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - antineoplastiske midler - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - lymfom, mantelcelle - antineoplastiske midler - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).